R C Hutubessy

Summary

Affiliation: World Health Organization
Country: Switzerland

Publications

  1. pmc Local perceptions of cholera and anticipated vaccine acceptance in Katanga province, Democratic Republic of Congo
    Sonja Merten
    Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute, PO Box, Socinstrasse 57, Basel 4002, Switzerland
    BMC Public Health 13:60. 2013
  2. pmc Costs of delivering human papillomavirus vaccination to schoolgirls in Mwanza Region, Tanzania
    Wilm Quentin
    Department of Health Care Management, Berlin University of Technology, Strasse des 17 Juni 135, Berlin, 10623, Germany
    BMC Med 10:137. 2012
  3. pmc Economic analyses to support decisions about HPV vaccination in low- and middle-income countries: a consensus report and guide for analysts
    Mark Jit
    Modelling and Economics Unit, Health Protection Agency, 61 Colindale Avenue, London NW9 5EQ, UK
    BMC Med 11:23. 2013
  4. pmc Systematic review of studies evaluating the broader economic impact of vaccination in low and middle income countries
    Rohan Deogaonkar
    Health Economics Unit, University of Birmingham, UK
    BMC Public Health 12:878. 2012
  5. pmc A case study using the United Republic of Tanzania: costing nationwide HPV vaccine delivery using the WHO Cervical Cancer Prevention and Control Costing Tool
    Raymond Hutubessy
    Immunization, Vaccines and Biologicals IVB Department, World Health Organization WHO, 20 Avenue Appia, 1211, Geneva 27, Switzerland
    BMC Med 10:136. 2012
  6. pmc Oral cholera vaccine use in Zanzibar: socioeconomic and behavioural features affecting demand and acceptance
    Christian Schaetti
    Department of Public Health and Epidemiology, Swiss Tropical Institute, PO Box, Socinstrasse 57, 4002 Basel, Switzerland
    BMC Public Health 9:99. 2009
  7. pmc Comparative review of three cost-effectiveness models for rotavirus vaccines in national immunization programs; a generic approach applied to various regions in the world
    Maarten J Postma
    Unit of PharmacoEpidemiology and PharmacoEconomics PE2, Department of Pharmacy, University of Groningen, Antonius Deusinglaan 1, 9713 AV, Groningen, The Netherlands
    BMC Med 9:84. 2011
  8. pmc Human papillomavirus vaccine introduction in low-income and middle-income countries: guidance on the use of cost-effectiveness models
    Mark Jit
    Modelling and Economics Unit, Health Protection Agency, London, UK
    BMC Med 9:54. 2011
  9. pmc Cost effectiveness of pediatric pneumococcal conjugate vaccines: a comparative assessment of decision-making tools
    Nathorn Chaiyakunapruk
    Center of Pharmaceutical Outcomes Research, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand
    BMC Med 9:53. 2011
  10. pmc Social and cultural features of cholera and shigellosis in peri-urban and rural communities of Zanzibar
    Christian Schaetti
    Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Basel, Switzerland
    BMC Infect Dis 10:339. 2010

Collaborators

Detail Information

Publications13

  1. pmc Local perceptions of cholera and anticipated vaccine acceptance in Katanga province, Democratic Republic of Congo
    Sonja Merten
    Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute, PO Box, Socinstrasse 57, Basel 4002, Switzerland
    BMC Public Health 13:60. 2013
    ..Clarification of vaccine acceptability prior to the introduction of a new vaccine provides important information for future policy and planning...
  2. pmc Costs of delivering human papillomavirus vaccination to schoolgirls in Mwanza Region, Tanzania
    Wilm Quentin
    Department of Health Care Management, Berlin University of Technology, Strasse des 17 Juni 135, Berlin, 10623, Germany
    BMC Med 10:137. 2012
    ..This study aimed to estimate the costs of a school-based HPV vaccination project in three districts in Mwanza Region (NCT ID: NCT01173900), Tanzania and to model incremental scaled-up costs of a regional vaccination program...
  3. pmc Economic analyses to support decisions about HPV vaccination in low- and middle-income countries: a consensus report and guide for analysts
    Mark Jit
    Modelling and Economics Unit, Health Protection Agency, 61 Colindale Avenue, London NW9 5EQ, UK
    BMC Med 11:23. 2013
    ..This report describes the consensus of an expert group convened by the World Health Organization, prioritizing key issues to be addressed when considering economic analyses to support HPV vaccine introduction in these countries...
  4. pmc Systematic review of studies evaluating the broader economic impact of vaccination in low and middle income countries
    Rohan Deogaonkar
    Health Economics Unit, University of Birmingham, UK
    BMC Public Health 12:878. 2012
    ..Measuring broader, long-term effects of vaccination on productivity and externalities could provide a more complete picture of the value of vaccines...
  5. pmc A case study using the United Republic of Tanzania: costing nationwide HPV vaccine delivery using the WHO Cervical Cancer Prevention and Control Costing Tool
    Raymond Hutubessy
    Immunization, Vaccines and Biologicals IVB Department, World Health Organization WHO, 20 Avenue Appia, 1211, Geneva 27, Switzerland
    BMC Med 10:136. 2012
    ..Tanzania is presented as a case study where the WHO C4P tool was used to cost and plan the roll-out of HPV vaccines nationwide as part of the national comprehensive cervical cancer prevention and control strategy...
  6. pmc Oral cholera vaccine use in Zanzibar: socioeconomic and behavioural features affecting demand and acceptance
    Christian Schaetti
    Department of Public Health and Epidemiology, Swiss Tropical Institute, PO Box, Socinstrasse 57, 4002 Basel, Switzerland
    BMC Public Health 9:99. 2009
    ....
  7. pmc Comparative review of three cost-effectiveness models for rotavirus vaccines in national immunization programs; a generic approach applied to various regions in the world
    Maarten J Postma
    Unit of PharmacoEpidemiology and PharmacoEconomics PE2, Department of Pharmacy, University of Groningen, Antonius Deusinglaan 1, 9713 AV, Groningen, The Netherlands
    BMC Med 9:84. 2011
    ....
  8. pmc Human papillomavirus vaccine introduction in low-income and middle-income countries: guidance on the use of cost-effectiveness models
    Mark Jit
    Modelling and Economics Unit, Health Protection Agency, London, UK
    BMC Med 9:54. 2011
    ..To provide information about the feasibility of using such models in a developing country setting, we evaluated models of HPV vaccination in terms of their capacity, requirements, limitations and comparability...
  9. pmc Cost effectiveness of pediatric pneumococcal conjugate vaccines: a comparative assessment of decision-making tools
    Nathorn Chaiyakunapruk
    Center of Pharmaceutical Outcomes Research, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand
    BMC Med 9:53. 2011
    ..With the aim to guide policymakers on their optimal use, we compared publicly available decision-making tools in relation to their methods, influential parameters and results...
  10. pmc Social and cultural features of cholera and shigellosis in peri-urban and rural communities of Zanzibar
    Christian Schaetti
    Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Basel, Switzerland
    BMC Infect Dis 10:339. 2010
    ..In the first step of a two-step strategy to examine determinants of cholera vaccine acceptance, this study identified social and cultural features of diarrhoeal illness for cholera control in endemic communities...
  11. pmc Results from evaluations of models and cost-effectiveness tools to support introduction decisions for new vaccines need critical appraisal
    Raymond Hutubessy
    Initiative for Vaccine Research, Immunization, Biologicals and Vaccines Department, World Health Organization, 20 Avenue Appia, CH 1210 Geneva, Switzerland
    BMC Med 9:55. 2011
    ....
  12. ncbi request reprint Critical issues in the economic evaluation of interventions against communicable diseases
    R C Hutubessy
    The Global Programme on Evidence for Health Policy, World Health Organization, 20 Avenue Appia, CH 1211 Geneva 27, Switzerland
    Acta Trop 78:191-206. 2001
    ..These improvements would better enable the evidence from economic analyses to enter the policy debate and be weighed against the other goals and objectives of the health system when allocating scarce resources...
  13. ncbi request reprint Stochastic league tables: communicating cost-effectiveness results to decision-makers
    R C Hutubessy
    Global Programme on Evidence for Health Policy GPE, World Health Organization, Geneva, Switzerland
    Health Econ 10:473-7. 2001
    ....